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Abstract
Cardiovascular	 risk	 prediction	 is	mainly	 based	on	 traditional	 risk	 factors	 that	 have	
been	validated	in	middle‐aged	populations.	However,	associations	between	these	risk	
factors	and	cardiovascular	disease	 (CVD)	attenuate	with	 increasing	age.	Therefore,	
for	older	people	the	authors	developed	and	internally	validated	risk	prediction	models	
for	fatal	and	non‐fatal	CVD,	(re)evaluated	the	predictive	value	of	traditional	and	new	
factors,	and	assessed	the	impact	of	competing	risks	of	non‐cardiovascular	death.	Post	
hoc	analyses	of	1811	persons	aged	70‐78	year	and	free	from	CVD	at	baseline	from	
the	preDIVA	study	(Prevention	of	Dementia	by	Intensive	Vascular	care,	2006‐2015),	
a	primary	care‐based	trial	that	included	persons	free	from	dementia	and	conditions	
likely	to	hinder	successful	long‐term	follow‐up,	were	performed.	In	2017‐2018,	Cox‐
regression	analyses	were	performed	for	a	model	including	seven	traditional	risk	fac‐
tors	only,	and	a	model	to	assess	incremental	predictive	ability	of	the	traditional	and	
eleven	new	factors.	Analyses	were	repeated	accounting	for	competing	risk	of	death,	
using	Fine‐Gray	models.	During	an	average	of	6.2	years	of	follow‐up,	277	CVD	events	
occurred.	Age,	 sex,	 smoking,	 and	 type	2	diabetes	mellitus	were	 traditional	 predic‐
tors	for	CVD,	whereas	total	cholesterol,	HDL‐cholesterol,	and	systolic	blood	pressure	
(SBP)	were	not.	Of	the	eleven	new	factors,	polypharmacy	and	apathy	symptoms	were	
predictors.	Discrimination	was	moderate	(concordance	statistic	0.65).	Accounting	for	
competing	risks	resulted	in	slightly	smaller	predicted	absolute	risks.	In	conclusion,	we	
found,	SBP,	HDL,	and	total	cholesterol	no	longer	predict	CVD	in	older	adults,	whereas	
polypharmacy	and	apathy	 symptoms	are	 two	new	 relevant	predictors.	Building	on	
the	selected	risk	factors	in	this	study	may	improve	CVD	prediction	in	older	adults	and	
facilitate	targeting	preventive	interventions	to	those	at	high	risk.
This	is	an	open	access	article	under	the	terms	of	the	Creat	ive	Commo	ns	Attri	butio	n‐NonCo	mmercial	License,	which	permits	use,	distribution	and	reproduction	
in	any	medium,	provided	the	original	work	is	properly	cited	and	is	not	used	for	commercial	purposes.
©	2019	The	Authors.	The Journal of Clinical Hypertension	Published	by	Wiley	Periodicals,	Inc.
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1  | INTRODUC TION
Current	 guidelines	 provide	 insufficient	 support	 for	 cardiovascular	
disease	(CVD)	management	in	older	persons.1	Whereas	a	large	num‐
ber	of	CVD	prediction	models	are	available	for	middle‐aged	adults	
(45‐65	 years),	 for	 older	 persons	 (≥70	 years)	 few	 CVD	 prediction	
models	exist.2‐4	Hence,	in	daily	practice,	general	practitioners	(GPs)	
generally	 extrapolate	 risk	 calculations	 from	 models	 derived	 from	
middle‐aged	populations	to	older	persons,	but	recent	findings	indi‐
cate	that	such	models	predict	poorly	for	this	group.5	This	 is	partly	
explained	by	the	diminished	or	even	reversed	associations	between	
traditional	risk	factors	and	CVD	in	older	persons.6	Moreover,	poten‐
tial	other	predictors	of	CVD	in	older	people	have	been	suggested,	
including	an	 increased	C‐reactive	protein	 (CRP)	as	a	marker	for	 in‐
flammation,3	 symptoms	of	apathy,7	polypharmacy,8	cholesterol‐as‐
sociated	circulating	apolipoproteins	A1	and	B,	and	gene	variants	of	
apolipoprotein	E	(APOE).9,10
While	traditionally	models	predict	a	ten‐year	risk	of	CVD	mor‐
tality,4,11,12	older	persons	and	their	GPs	favor	models	assessing	risk	
of	developing	any	major	atherosclerotic	event	within	a	shorter	time	
span.13	 Hence,	 GPs	 pragmatically	 and	 intuitively	 weigh	 additional	
factors	 including	 frailty,	multimorbidity,	quality	of	 life,	 and	 life	ex‐
pectancy	in	their	decision	whether	or	not	to	start	preventive	treat‐
ment.14	 Furthermore,	while	 risk	 of	 death	 from	 non‐cardiovascular	
causes	 competes	with	CVD	events,	most	 existing	models	 in	 older	
persons	do	not	account	for	this,2,4	and	so	fueling	overestimation	of	
CVD	risks.5,15
The	aim	of	this	paper	was	therefore	to	develop	and	internally	val‐
idate	a	risk	prediction	model	for	fatal	and	non‐fatal	CVD,	for	people	
aged	70	years	and	over,	by	(re)evaluating	the	predictive	value	of	tra‐
ditional	 factors,	 exploring	additional	 factors	and	 taking	competing	
risks	of	non‐cardiovascular	death	into	account.
2  | METHODS
This	study	is	reported	following	the	“STrengthening	the	Reporting	of	
OBservational	studies	in	Epidemiology”	checklist.16
2.1 | Study population
Patients	partook	in	Prevention	of	Dementia	by	Intensive	Vascular	
care	(preDIVA),	a	cluster‐randomized	controlled	trial	carried	out	in	
primary	care	in	the	Netherlands.	The	methodology	of	preDIVA	has	
been	described	in	detail.17	In	short,	participants	aged	70‐78	years	
and	 free	 from	dementia	 and	 conditions	 likely	 to	 hinder	 success‐
ful	long‐term	follow‐up	according	to	their	GP	(eg,	terminal	illness,	
alcoholism)	were	eligible.	There	was	no	sex	bias	 in	 the	 selection	
of	 participants.	Of	6762	eligible	 older	 adults	 from	116	GP	prac‐
tices	within	26	health	care	centers	(HCC)	in	the	Netherlands,	3526	
(52.1%)	 signed	written	 informed	 consent.	 Recruitment	was	 from	
June	 2006	 through	March	 2009.	 The	 primary	 outcome	was	 de‐
mentia,	 and	 main	 secondary	 outcomes	 were	 incident	 CVD	 and	
cardiovascular	and	all‐cause	mortality.	The	 final	assessment	was	
carried	out	between	January	2014	and	March	2015.	For	the	pre‐
sent	post	hoc	analyses,	all	preDIVA	participants	without	a	history	
of	 CVD	 at	 baseline	were	 included.	 Since	 no	 effect	 of	 the	 inter‐
vention	was	found	on	CVD,	neither	in	the	total	study	population	
nor	 in	 the	participants	without	a	history	of	CVD,	 the	population	
was	considered	a	cohort.17,18	The	preDIVA	study	was	approved	by	
the	Medical	 Ethics	Committee	 of	 the	Academic	Medical	 Center,	
Amsterdam	(MEC	05/093	06.17.0640).
2.2 | Cardiovascular risk factors
At	baseline,	a	practice	nurse	at	 the	GP	practice	assessed	data	on	
socio‐demographic	 characteristics,	 cardiovascular	 risk	 factors	
(blood	 pressure,	 type	 2	 diabetes	 mellitus	 [T2DM],	 cholesterol,	
BMI,	 and	 smoking	 habits),	 CRP,	 apolipoproteins,	 current	 medica‐
tion,	 symptoms	 of	 apathy,	 family	 history	 of	 CVD,	 and	 the	 APOE	
genotype.
The	 traditional	 risk	 factors	were	 those	used	 in	 the	SCORE‐OP	
(SCORE	for	older	people)	model:	age,	sex,	systolic	blood	pressure,	
smoking	 status,	 total	 cholesterol	 (TC),	 high‐density	 lipoprotein	
cholesterol	 (HDL),	 and	 T2DM.4	 Eleven	 potential	 additional	 CVD	
predictors	were	selected	based	on	the	literature	and	availability	 in	
our	dataset:	family	history	of	CVD,	polypharmacy,	antihypertensive	
medication	 (AHM)	 use,	 physical	 activity,	 BMI,	 apathy	 symptoms,	
CRP,	 low‐density	 lipoprotein	 cholesterol	 (LDL),	 apolipoprotein	 A1	
(ApoA1),	apolipoprotein	B	(ApoB),	and	APOE	genotype.	Family	his‐
tory	of	CVD	was	defined	as	a	CVD	event	in	first‐degree	relatives	be‐
fore	the	age	of	60.	Polypharmacy	was	defined	as	the	chronic	use	of	
drugs	from	≥5	ATC	(Anatomical	Therapeutic	Chemical	Classification)	
groups	(ATC3	level).19	Physical	activity	was	measured	with	the	LASA	
physical	 activity	 questionnaire	 (LAPAQ)	 and	 defined	 as	 physically	
active	according	 to	 the	World	Health	Organization.17,20	Symptoms	
of	 apathy	were	measured	with	 the	 three	 apathy	 items	 of	 the	 15‐
item	Geriatric	Depression	Scare	(GDS‐3A;	range	0‐3	points,	higher	
scores	indicating	more	apathy).7	CRP,	LDL,	ApoA1,	ApoB,	and	APOE	
were	measured	in	serum.	APOE	genotype	was	included	as	a	nominal	
variable.
2.3 | Outcome
The	outcome	was	a	first	cardiovascular	event	(CVD	mortality,	myo‐
cardial	infarction,	stroke,	transient	ischemic	attack,	angina	pectoris,	
and	 peripheral	 arterial	 disease).	 In	 concordance	with	well‐known	
cardiovascular	 prediction	 models	 in	 adults,	 a	 pragmatic	 outcome	
measure	was	chosen,	which	meets	GP	and	older	patients’	prefer‐
ences	 and	 is	 directly	 applicable	 in	 clinical	 practice.2,12,13 During 
two‐year	assessments,	self‐reported	history	of	cardiovascular	mor‐
bidity	was	collected	and	cross‐checked	with	the	electronic	medical	
record	(EMR).	In	73%	of	deaths,	the	cause	could	be	retrieved	from	
the	 EMR	 and	 hospital	 discharge	 letters.	 Subsequently,	 this	 infor‐
mation	 was	 evaluated	 by	 an	 independent	 outcome	 adjudication	
committee.17
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2.4 | Statistical analyses
Analyses	were	performed	between	June	2017	and	December	2018.	
Missing	values	for	traditional	and	additional	predictors	were	imputed	
using	multivariate	imputation	by	chained	equations,	using	the	R	library	
“mice.”21	This	way,	twenty	imputed	datasets	with	no	missing	data	on	
traditional	 and	 additional	 risk	 factors	 were	 generated.	 All	 analyses	
presented	here	were	performed	on	all	twenty	datasets;	subsequently,	
these	estimates	were	pooled	into	the	final	result	according	to	Rubin's	
rules,	taking	into	account	variance	between	and	within	datasets.
Since	 the	preDIVA	 study	was	originally	designed	as	 a	 trial,	we	
tested	whether	there	was	a	difference	between	the	survival	curves	
for	CVD	based	on	“study	group.”	Since	this	was	not	significantly	as‐
sociated	with	CVD	risk	(P‐value	for	chi‐square	test	for	the	survival	
curves	in	the	two	treatment	groups	was	0.84),	the	study	population	
was	further	treated	as	a	cohort.
Cox‐proportional	 hazard	models	were	 used	 to	 derive	 the	 func‐
tions	for	estimating	CVD	morbidity	and	mortality,	using	the	R	library	
“survival.”22	Time	to	event	was	defined	as	time	from	baseline	assess‐
ment	to	first	cardiovascular	event,	or	if	no	event	occurred	cases	were	
censored	at	the	last	two‐yearly	study	assessment	that	the	participant	
attended.	In	model	1,	the	seven	traditional	risk	factors	were	included.	
In	model	2,	from	the	7	traditional	and	11	additional	factors,	relevant	
predictors	 were	 selected	 using	 backward	 selection,	 with	 the	 AIC	
stopping	rule.23	This	is	an	extensively	used	selection	method	in	clini‐
cal	prediction23,24	that	seems	to	achieve	better	parsimony	in	smaller	
datasets	compared	to	modern	tree‐based	methods.23	Variables	that	
were	selected	in	>33%	of	the	20	imputed	datasets	were	kept	in	the	
model.	Age	was	forced	in	the	model,	since	previous	studies	agreed	on	
age	as	a	risk	factor,	and	the	age	range	in	this	population	was	limited.	
The	proportional	hazard	assumption	of	the	Cox	model	was	assessed	
by	examining	the	Schoenfeld	residuals,	and	splines	were	used	to	ver‐
ify	whether	linearity	of	continuous	variables	would	hold.
Subsequently,	we	 tested	 for	 interaction	 among	 traditional	 risk	
factors,	because	 the	association	between	potential	 risk	 factors	on	
the	outcome	might	depend	on	other	risk	factors.4,6	Models	were	not	
stratified	 for	 sex	 as	none	of	 the	associations	 significantly	differed	
between	men	and	women.	Furthermore,	we	checked	whether	multi‐
collinearity	between	risk	factors	existed	among	cholesterol‐related	
variables	 (TC,	HDL,	LDL,	ApoA1,	ApoB),	among	the	use	of	antihy‐
pertensive	and	cholesterol‐lowering	medication	and	polypharmacy,	
and	between	polypharmacy,	SBP,	and	cholesterol‐related	variables.	
The	method	as	proposed	by	Fine	and	Gray	was	used	to	account	for	
competing	 risks	 of	 non‐cardiovascular	 death,	 using	 the	 R	 library	
“riskRegression.”25,26	The	event	was	defined	as	first	CVD	event,	the	
competing	event	as	non‐cardiovascular	mortality.
2.5 | Model performance and discriminative ability
Discriminative	ability	was	calculated	and	compared	between	models	
using	the	inverse	probability	of	censoring	weighted	(IPCW)	C‐index.	
Models	 were	 internally	 validated	 using	 bootstrapping.	 Calibration	
slopes	 were	 generated	 for	 100	 bootstrap	 samples	 per	 imputed	
dataset.	The	resulting	shrinkage	factors	after	bootstrapping	for	the	
respective	models	were	used	to	adjust	for	overestimation	of	the	re‐
gression	coefficients	and	overfitting	of	the	models.
2.6 | Sensitivity analyses
To	evaluate	the	effect	of	missing	values,	that	is,	the	imputation	process,	
we	performed	a	complete	case	analysis	for	model	1.	Furthermore,	to	
explore	 the	 impact	 of	 cardiovascular	medication,	 analyses	were	 re‐
peated	in	subgroups	of	participants	(a)	without	baseline	cardiovascu‐
lar	medication	use,	(b)	without	cardiovascular	medication	at	baseline	
nor	 during	 the	 first	 4	 years	 of	 follow‐up,	 and	 (c)	 in	 the	 control	 and	
intervention	condition	of	preDIVA.	Next,	we	explored	the	impact	on	
predictive	value	and	predictor	selection	of	using	cardiovascular	medi‐
cation	 (antihypertensive	 and	 cholesterol‐lowering	 drugs)	 in	 patients	
with	the	highest	cardiovascular	risk.	For	this,	backward	selection	was	
performed	on	a	model	 including	all	18	variables,	 in	which,	 for	poly‐
pharmacy,	 all	 but	 cardiovascular	 medications	 were	 counted.	 Lastly,	
baseline	cholesterol‐lowering	medication	use	was	added	as	a	variable	
to	the	full	model	to	explore	its	impact	on	cholesterol‐related	variables.
3  | RESULTS
Of	2254	preDIVA	participants	without	prior	CVD	at	baseline,	1811	
(80%)	had	information	on	CVD	and	mortality	during	follow‐up.	The	
443	participants	excluded	from	the	analyses	had	 less	often	T2DM	
(11.7%	vs	16.7%),	were	more	often	smokers	(15.8%	vs	11.8%)	and	not	
physically	active	(82.4%	vs	89.7%),	received	more	often	<7	years	of	
education	(21.8%	vs	30.0%),	and	had	more	often	the	APOE	Ɛ3	‐	Ɛ4	
variant	(20.2%	vs	22.6%)	compared	to	those	included	in	the	analyses	
(Table	S1).	Of	the	1811	included	participants,	429	(24%)	had	missing	
information	on	one	or	more	risk	factors;	for	each	risk	factor,	the	num‐
ber	of	missings	is	summed	in	the	legend	of	Table 1.	After	multivariate	
imputation,	twenty	imputed	datasets	containing	the	1811	cases	with	
no	missing	data	were	available	for	analyses.	Baseline	characteristics	
are	shown	in	Table	1.	During	a	median	follow‐up	of	6.2	years	(inter‐
quartile	range	3.9‐7.1	years),	277	first	CVD	events	occurred,	of	which	
131	coronary	heart	disease	 (CHD)	events.	This	corresponds	with	a	
5‐year	cumulative	incidence	of	11.5%	of	CVD	events.
For	 all	 traditional	 and	 additional	 predictors,	 linear	 relations	
between	 predictors	 and	 the	 outcome	 variable	 were	 appropriate.	
Proportional	 hazard	 assumptions	were	met,	 and	 interaction	 terms	
among	traditional	predictors	were	not	significant	and	therefore	dis‐
regarded	in	the	final	models.	There	was	only	relevant	multicollinear‐
ity	among	cholesterol‐related	variables	(ApoB*TC	[Pearson's	r	0.79],	
ApoB*LDL	[Pearson's	r	0.84],	and	TC*LDL	[Pearson's	r	0.92]).
Table 2	 shows	 the	 results	of	 the	Cox‐regression	analyses	after	
shrinkage,	when	 including	all	 traditional	 risk	 factors	 (model	1)	and	
when	 including	 variables	 that	 remained	 relevant	 after	 backward	
selection	(model	2).	Within	model	1,	the	strongest	predictors	were	
active	smoking	 (HR	1.85	 [95%	CI	1.41‐2.43]),	T2DM	(1.63	 [95%	CI	
1.24‐2.13]),	and	male	sex	(1.32	[95%	CI	1.05‐1.65]).	Of	the	additional	
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potential	 predictors,	 polypharmacy	 (1.41	 [95%	 CI	 1.08‐1.83])	 and	
apathy	symptoms	(1.19	per	point	 increase	on	the	GDS‐3A	[95%	CI	
1.05‐1.34])	remained	in	model	2.
To	facilitate	the	estimation	of	the	predicted	5‐year	risk	of	com‐
bined	 cardiovascular	 morbidity	 and	 mortality	 for	 older	 persons,	
Table	 S2	 shows	beta‐coefficients	 for	 each	 risk	 factor	 of	models	1	
TA B L E  1  Baseline	characteristics	of	participantsa 
Baseline characteristics Overall (n = 1811)
Without incident CVD 
(n = 1534)
With incident CVD 
(n = 277) P‐value
Demographics
Age	in	y,	mean	(SD) 74.1	(2.4) 74.1	(2.4) 74.2(2.5) 0.36
Sex,	male	(%) 717	(39.6) 588	(38.3) 129	(46.6) 0.01
Educational	level,	no.	(%)
<7	y 392	(21.8) 330	(21.5) 62	(22.4) 0.39
7‐12	y 1169	(65.1) 1000	(65.2) 169	(61.0)
>12	y 235	(13.1) 193	(12.6) 42	(15.2)
Caucasian,	no.	(%) 1741	(97.8) 1474	(96.1) 267	(96.4) 0.11
Traditional	cardiovascular	risk	factors
SBP	in	mm	Hg,	mean	(SD) 155.6	(20.6) 154.9	(20.2) 158.9	(22.2) 0.01
Total	cholesterol	in	mmol/L,	mean	(SD) 5.51	(1.04) 5.52	(1.03) 5.42	(1.12) 0.16
HDL‐cholesterol	in	mmol/L,	mean	(SD) 1.56	(0.42) 1.57	(0.42) 1.50	(0.40) 0.01
Type	2	diabetes,	no.	(%) 302	(16.7) 236	(15.4) 66	(23.8) <0.001
Current	smoking,	no.	(%) 214	(11.8) 161	(10.5) 53	(19.1) <0.001
Additional	cardiovascular	risk	factors
LDL	cholesterol	in	mmol/L,	mean	(SD) 3.35	(2.74‐3.95) 3.36	(2.75‐3.95) 3.23	(2.63‐3.93) 0.23
C‐reactive	protein	(CRP),	mg/L,	median	(IQR) 2.00	(1.00‐4.00) 2.00	(1.00‐3.50) 2.00	(1.00‐4.00) 0.03
Circulating	apolipoproteins	A1	(g/L),	mean	(SD) 1.51	(0.29) 1.52	(0.29) 1.46	(0.28) <0.001
Circulating	apolipoproteins	B	(g/L),	mean	(SD) 1.00	(0.25) 1.00	(0.25) 1.00	(0.26) 0.96
Apolipoprotein	E	gene	variants,	no.	(%)
Ɛ2	‐	Ɛ2 7	(0.4) 5	(0.3) 2	(0.7) 0.89
Ɛ2	‐	Ɛ3 237	(13.1) 202	(13.2) 35	(12.6)
Ɛ3	‐	Ɛ3 890	(49.1) 759	(49.5) 131	(47.3)
Ɛ3	‐	Ɛ4 365	(20.2) 311	(20.3) 54	(19.5)
Ɛ4	‐	Ɛ4 35	(1.9) 31	(2.0) 4	(1.4)
BMI	(kg/m2),	mean	(SD) 27.3	(4.3) 27.34	(4.3) 27.36	(4.2) 0.93
Polypharmacy	(≥5	medicine),	no.	(%) 378	(20.9) 299	(19.5) 79	(28.5) <0.001
Use	of	antihypertensive(s),	no	(%) 760	(42.0) 625	(40.7) 135	(48.7) 0.01
Family	history	of	CVDb,	no.	(%) 262	(14.5) 217	(14.1) 45	(16.2) 0.40
Physically	active	(WHO),	no.	(%) 1587	(89.7) 1347	(87.8) 240	(86.6) 0.33
Symptoms	of	apathy	(GDS3A),	no.	(%)
0 1042	(57.7) 906	(59.1) 136	(49.1) 0.01
1 484	(26.8) 402	(26.2) 82	(29.6)
2 199	(11.0) 160	(10.4) 39	(14.1)
3 80	(4.4) 61	(4.0) 19	(6.9)
Note: Population	without	a	history	of	CVD.	Percentages	reflect	the	proportion	within	participants	with	available	information.	The	following	variables	
had	missing	data	(n):	educational	level	(15),	caucasian	(30),	SBP	(2),	total	cholesterol	(34),	HDL	(32),	current	smoking	(2),	LDL	(34),	CRP	(60),	apolipopro‐
tein	A1	(117),	apolipoprotein	B	(117),	APO	E	gene	variants	(277),	BMI	(1),	use	of	antihypertensive(s)	(6),	physically	active	(41),symptoms	of	apathy	(6).
Abbreviations:	BMI,	body	mass	index;	CVD,	cardiovascular	disease;	GDS3A,	three	apathy	items	on	the	15‐item	geriatric	depression	scale;	HDL,	high‐
density	lipoprotein;	IQR,	interquartile	range;	LDL,	low‐density	lipoprotein;	SBP,	systolic	blood	pressure;	SD,	standard	deviation;	WHO,	World	Health	
Organization.
aBased	on	non‐imputed	data.	
bFamily	history	of	CVD	in	first‐degree	relatives	before	the	age	of	60.	
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and	2,	and	the	baseline	hazard	for	a	5‐year	period,	for	a	hypothetical	
person	with	all	variables	set	at	zero.	To	get	an	impression	of	absolute	
risks	when	expanding	CVD	risk	prediction	in	the	Dutch	guideline	to	
age	70	 and	75,	 a	 chart	 based	on	 traditional	 risk	 factors	 (model	 1,	
Equation	S1)	was	developed,	presenting	five‐year	absolute	risks	of	
CVD	morbidity	or	mortality	(Figure	S1).27
3.1 | Competing risks of non‐cardiovascular death
During	the	6.2	years	of	follow‐up,	94	non‐cardiovascular	deaths	oc‐
curred.	Compared	to	models	1	and	2,	not	accounting	for	competing	risk	
of	death,	the	beta‐coefficients	and	HRs	for	the	subdistribution	in	the	
competing	risk	models	(models	3	and	4)	are	slightly	smaller,	represent‐
ing	a	more	meaningful	prediction	of	absolute	risks.(Table	2,	Table	S2)	
Based	on	Equation	S1,	and	the	baseline	hazard	and	beta‐coefficients	
of	model	3,	charts	presenting	5‐year	absolute	risks	of	CVD	morbid‐
ity	or	mortality	accounting	for	competing	risk	of	non‐cardiovascular	
death	for	persons	aged	70	and	75	years	were	developed	(Figure	S2).
3.2 | Model performance
The	discriminative	performance	of	the	models	was	moderate	(IPCW	
C‐statistic	0.663	in	model	1	to	0.642	in	model	4)	(Table	2),	and	dif‐
ferences	were	small.	Using	the	six	factors	of	model	2	and	4	resulted	
in	similar	predictive	ability	to	using	the	seven	factors	of	models	1	and	
3.	Performance	of	a	model	containing	all	18	variables	was	similar	to	
the	other	models	(IPCW	C‐statistic	0.643).
For	 models	 1	 and	 2,	 the	 shrinkage	 factors	 were	 0.9028	 and	
0.9326,	and	for	models	3	and	4,	the	shrinkage	factors	were	0.9013	
and	0.9213,	respectively.	Calibration	risk	was	plotted	for	all	models	
in	Figure	S3.
3.3 | Sensitivity analyses
Analyses	in	the	subgroup	with	complete	cases	(n	=	1382),	the	subgroup	
without	cardiovascular	medication	at	baseline	(n	=	920),	the	subgroup	
without	cardiovascular	medication	at	baseline	nor	the	first	4	years	of	
follow‐up	 (n	=	726),	 and	 subgroups	 for	 the	 control	 and	 intervention	
condition	of	preDIVA	did	not	alter	the	results	for	model	1	(Table	S3).
In	 a	 sensitivity	 analysis	 defining	 polypharmacy	 as	 ≥5	 medi‐
cines,	excluding	cardiovascular	medication,	polypharmacy	was	no	
longer	significantly	associated	with	the	outcome.	After	backward	
selection,	smoking	status,	T2DM,	and	apathy	symptoms	remained	
relevant	 predictors	 (Table	 S4,	Model	 5).	 In	 a	 sensitivity	 analysis	
adding	 cholesterol‐lowering	 drugs	 as	 a	 variable	 to	 the	 complete	
model	 with	 18	 variables,	 the	 HR	 for	 cholesterol‐lowering	 drugs	
was	1.02	(95%	CI	0.72‐1.43)	and	HRs	of	the	other	18	variables	in	
the	model	did	not	change.
TA B L E  2  Hazard	ratios	for	traditional	and	additional	risk	factors	for	CVD	morbidity	and	mortality
Predictor category Predictors
Cox‐PH models Fine‐Gray models
Model 1: traditional 
risk factors
Model 2: variables 
selected through 
backward selectiona
Model 3: 
traditional risk 
factors
Model 4: variables 
of model 2
HR (95% CI) HR (95% CI) HR (95% CI)b HR (95% CI)b
Traditional	risk	factors Age 1.03	(0.99‐1.08) 1.03	(0.98‐1.08) 1.03	(0.99‐1.08) 1.03	(0.98‐1.08)
Male 1.32	(1.05‐1.65) 1.45	(1.16‐1.81) 1.31	(1.04‐1.64) 1.42	(1.14‐1.78)
Smoking	status 1.85	(1.41‐2.43) 1.83	(1.38‐2.43) 1.76	(1.34‐2.30) 1.73	(1.31‐2.28)
SBP	per	mm	Hg 1.01	(1.00‐1.01)  1.01	(1.00‐1.01)  
Total	cholesterol	per	
mmol/L
1.05	(0.94‐1.18)  1.05	(0.93‐1.18)  
HDL	per	mmol/L 0.81	(0.61‐1.09)  0.83	(0.63‐1.10)  
T2DM 1.63	(1.24‐2.13) 1.44	(1.09‐1.89) 1.60	(1.23‐2.08) 1.40	(1.07‐1.83)
Additional	risk	factors Polypharmacy  1.41	(1.08‐1.83)  1.40	(1.08‐1.82)
Symptoms	of	apathy  1.19	(1.05‐1.34)  1.18	(1.05‐1.33)
Performance IPCW	C‐index 0.651 0.643 0.641 0.632
Note: Larger	numbers	indicate	better	performance.
All	HRs	shown	after	shrinkage.	Model	3	and	4	account	for	competing	risks	of	death.
Abbreviations:	95%	CI,	95%	confidence	interval;	BMI,	body	mass	index;	Cox‐PH,	Cox‐proportional	hazard;	CRP	C‐reactive	protein;	CVD,	cardiovascu‐
lar	disease;	HDL,	high‐density	lipoprotein;	IPCW	C‐index,	inverse	probability	of	censoring	weighted	concordance‐index;	LDL,	low‐density	lipopro‐
tein;	SBP,	systolic	blood	pressure;	T2DM,	type	2	diabetes	mellitus.
aVariables	tested	in	the	backward	procedure:	age,	sex,	smoking	status,	SBP,	total	cholesterol,	HDL,	T2DM,	family	history	of	CVD,	polypharmacy,	
antihypertensive	medication	use,	physical	activity,	BMI,	symptoms	of	apathy,	CRP,	LDL,	apolipoprotein	A1,	apolipoprotein	B,	and	apolipoprotein	E	
genotype.	Age	was	forced	into	the	model.	
bHazard	ratios	for	the	subdistribution	hazards	of	the	Fine	and	Gray	model.25 
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4  | DISCUSSION
In	our	study	among	1811	community	dwelling	older	persons	with	
no	history	of	CVD,	age,	sex,	smoking	status,	T2DM,	polypharmacy,	
and	symptoms	of	apathy	were	predictors	for	CVD,	whereas	total	
cholesterol,	 HDL‐cholesterol,	 SBP,	 and	 other	 additional	 factors	
were	not.
All	models	had	moderate	ability	to	predict	CVD.	The	model	tak‐
ing	into	account	competing	risk	of	non‐cardiovascular	death	offers	
more	meaningful	estimates	for	the	risk	of	cardiovascular	events	 in	
this	older	population.
Few	models	of	varying	quality	predicting	5‐year	risk	of	combined	
CVD	morbidity	and	mortality	in	persons	aged	70	and	over	have	been	
published,	and	results	regarding	the	predictive	ability	of	traditional	
risk	factors	are	conflicting.	In	some	studies	selecting	predictors	for	
CVD	mortality	in	older	people,	all	traditional	risk	factors	contributed	
to	risk	prediction,	whereas	in	others,	none	of	the	traditional	risk	fac‐
tors	did.4,28‐30
In	 two	 studies,	 SBP,	HDL‐cholesterol,	 and	 total	 cholesterol	 re‐
mained	among	the	best	predictors	for	combined	CVD	morbidity	and	
mortality,31,32	and	in	one	study,	SBP	had	no	predictive	value	and	TC	
and	HDL	only	when	 no	 new	 variables	 (CRP,	 homocysteine,	waist‐
to‐hip	 ratio,	 and	 self‐reported	 health)	 were	 added	 to	 the	model.3 
In	 another	 study,	T2DM,	 smoking,	 and	HDL,	but	not	SBP	and	TC,	
were	predictors	for	coronary	heart	disease.31	In	our	study,	SBP,	total	
cholesterol,	 and	HDL‐cholesterol	 had	no	 relevant	 predictive	 value	
beyond	the	six	selected	predictors,	which	is	in	line	with	the	theory	
of	 reverse	 epidemiology	 in	 older	 persons.6,28	 Differences	 among	
studies	 can	 be	 explained	 by	 the	 differences	 in	 study	 populations	
(eg,	age	 range,	exclusion	criteria),	outcome	measures	 (eg	 fatal	ver‐
sus	combined	fatal	and	non‐fatal	disease	and	coronary	heart	disease	
versus	CVD),	the	set	of	traditional,	and	new,	predictors	added	in	the	
model,	and	definitions	and	handling	of	variables	in	the	models.	More	
high‐quality	 studies	 are	 needed	 before	 the	 traditional	 risk	 factors	
that	were	disregarded	in	our	study,	can	be	finally	disregarded	as	pre‐
dictors	for	CVD	in	older	people.
The	 incremental	predictive	ability	of	polypharmacy	and	apathy	
symptoms	for	CVD	in	older	people	has	not	been	studied	before.	In	
our	 study,	 these	 two	 variables	were	 predictors	 for	 fatal	 and	 non‐
fatal	CVD	in	older	persons.	Polypharmacy	as	a	predictor	 is	consis‐
tent	with	a	previous	study	with	1196	older	people	(aged	≥	65	years)	
where	 “number	 of	 medications”	 was	 identified	 as	 an	 additional	
predictor	 for	 fatal	 CVD.29	 Polypharmacy	 is	 a	 complex	 product	 of	
patient	 characteristics,	physician	management,	 and	patient	prefer‐
ences.14	However,	it	is	easy	to	ascertain	and	can	therefore	easily	be	
implemented	 in	 risk	 prediction.	 When	 cardiovascular	 medication	
was	excluded	from	the	medication	counted	to	assess	polypharmacy,	
polypharmacy	no	longer	added	any	relevant	predictive	ability.	This	
indicates	that	cardiovascular	medication	adds	to	the	predictive	value	
of	 polypharmacy,	 although	 the	 use	 of	 antihypertensive	 or	 choles‐
terol‐lowering	medication	were	no	predictors	on	their	own.	Besides,	
this	does	not	disqualify	polypharmacy	as	a	predictor,	since	in	daily	
practice	 persons	 with	 and	 without	 cardiovascular	 medication	 re‐
ceive	risk	assessments.	Apathy	symptoms	have	recently	been	inde‐
pendently	associated	with	CVD	in	older	people	(mean	age	74	years)	
in	a	large	meta‐analysis	of	individual	participant	data	(n	=	74	625).7 
Polypharmacy	and	apathy	symptoms	are	promising	new	predictors	
for	CVD	in	old	age	that	are	easy	to	ascertain	without	extra	costs	or	
invasive	tests.	Since	there	are	no	other	studies	testing	their	predic‐
tive	value,	our	results	need	to	be	confirmed	in	other	cohorts	of	older	
people.
In	previous	studies,	circulating	concentrations	of	apolipoproteins	
(ApoA1	[protective	factor]	and	ApoB	[risk	factor])	as	well	as	apoli‐
poprotein	E	gene	variants	have	been	associated	with	incident	CVD	
in	populations	including	older	persons.9,10	In	our	study,	they	did	not	
have	incremental	predictive	value.	ApoA1	and	ApoB	are	correlated	
with	serum	cholesterol	(TC,	HDL,	and	LDL),	which	did	not	relevantly	
improve	predictive	value	either.	The	incremental	predictive	value	of	
BMI,6	CRP,3,28	and	family	history	of	CVD	has	previously	been	stud‐
ied	in	older	people,	yielding	conflicting	results.32	Our	study	suggests	
that	BMI,	CRP,	physical	activity,	and	family	history	of	CVD	are	not	
useful	in	predicting	CVD	in	older	persons.
We	 provided	 models	 with	 and	 without	 accounting	 for	 com‐
peting	 risk.	Norway	 is	 the	 first	country	 to	 include	CVD	prediction	
models	 that	 account	 for	 competing	 risk	 of	 death	 in	 their	 clinical	
guidelines.15	Absolute	risks	are	generally	slightly	lower	compared	to	
risks	calculated	 in	models	 ignoring	or	censoring	competing	events.	
Implementing	competing	risks	into	prediction	models	is	preferable,	
since	it	gives	real	life,	and	therefore,	more	meaningful	estimates	of	
the	older	persons’	absolute	CVD	risk.
Discriminatory	performance	in	most	CVD	prediction	models	for	
older	people	 is	modest.	The	models	presented	here,	with	IPCW	c‐
indexes	of	0.63	and	0.64	for	selected	risk	factors	with	and	without	
accounting	 for	 competing	events,	 are	no	exception.	C‐statistics	of	
other	models	developed	in	populations	of	older	people	ranged	from	
0.635	to	0.74.4
4.1 | Limitations
A	strength	of	 this	 study	 is	 the	external	 validity.	 The	population	 is	
comparable	to	a	population	from	national	cohort	data	in	terms	of	risk	
factor	occurrence,33	and	incidence	of	CVD	morbidity	and	mortality	
(5‐year	cumulative	incidence	was	13.0%	and	10.4%	in	two	previously	
published	population‐based	cohorts	of	older	people,	and	11.5%	 in	
our	 study).3,32	 Additionally,	 there	were	 few	 exclusion	 criteria,	 and	
excluded	 participants	 are	 generally	 not	 considered	 for	 CVD	 risk	
calculation.	The	24%	of	participants	with	missing	predictors	at	the	
baseline	were	retained	in	the	analyses	by	using	multiple	imputation.	
Besides,	 results	of	 complete	case	analyses	did	not	differ	 from	 the	
main	analyses.	The	models,	 therefore,	appear	valid	for	use	 in	non‐
acute	primary	care	consultations.
Additional	value	 is	added	by	 this	 study	as	 it	presented	various	
models	to	facilitate	comparison	to	existing	models.	While	CHD	and	
non‐CHD	events	may	have	different	predictors,	with	the	pragmatic	
combined	outcome	measure	of	CVD	morbidity	and	mortality,	within	
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a	 5‐year	 prediction	 horizon,	 we	 concede	 to	 GP	 and	 older	 patient	
preferences.13
Treatment	 of	 baseline	 risk	 factors	 could	 have	 reduced	 overall	
predictive	 ability	 in	our	population	of	older	people.34	However,	 in	
analyses	 including	cholesterol‐lowering	and	antihypertensive	med‐
ication	 as	 variables,	 and	 an	 analysis	 excluding	 participants	 that	
started	cardiovascular	medication	(“treatment	drop‐ins”),	results	did	
not	differ	from	the	main	analyses.	This	indicates	that	medication	use	
did	not	influence	the	predictive	value	of	our	predictors,	and	that	the	
models	can	be	used	in	 individuals	with	and	without	cardiovascular	
medication.
Multiple	testing	on	a	relatively	small	number	of	events	(n	=	277)	
may	 result	 in	 false‐positive	 or	 false‐negative	 results,	 but	 our	 re‐
sults	 are	 robust	 using	 different	methods,	 and	 in	 sensitivity	 analy‐
ses.	 Finally,	 evaluation	of	 additional	 factors	was	 limited	 to	 factors	
available	 in	our	dataset.	There	might	be	other	 factors	with	 strong	
predictive	ability	not	available	in	our	data.28,35
Our	 results	provide	 insight	 into	absolute	 risk	of	CVD	for	older	
persons.	However,	treatment	implications	are	patient	to	continued	
discussion.	Especially	 in	older	people,	 the	optimal	cutoff	value	 for	
starting	treatment	is	unknown.1	In	middle‐aged	adults	weighing	risks	
and	benefits	from	treatment,	a	cutoff	of	20%	of	CVD	morbidity	and	
mortality	in	the	next	10	years	is	generally	agreed	on.1	With	increas‐
ing	 age,	 shorter	 life	 expectancy,	 and	 multimorbidity,	 the	 balance	
between	potential	harms	and	benefits	of	long‐term	medication	may	
shift,	requiring	doctors	to	reconsider	whether	(continued)	cardiovas‐
cular	medication	is	still	justified.36
In	conclusion,	of	the	traditional	risk	factors,	only	age,	sex,	smok‐
ing	 status,	 and	 T2DM	 showed	 predictive	 ability	 in	 people	 aged	
70‐78	 years,	whereas	 total	 cholesterol,	 HDL‐cholesterol,	 and	 SBP	
did	not.	From	a	set	of	eleven	additional	factors,	polypharmacy	and	
apathy	symptoms	were	identified	as	new	predictors	for	CVD	in	this	
age	group.	Accounting	for	competing	risk	of	death	resulted	in	more	
meaningful	prediction.	Building	on	the	selected	risk	 factors	 in	 this	
study	combined	with	other	potential	risk	factors	may	improve	pre‐
diction	of	CVD	in	older	adults	and	facilitate	targeting	preventive	in‐
terventions	to	those	at	high	risk.
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